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Abstract Recurrent mutations affecting the histone H3.3
residues Lys27 or indirectly Lys36 are frequent drivers of
pediatric high-grade gliomas (over 30 % of HGGs). To
identify additional driver mutations in HGGs, we investi-
gated a cohort of 60 pediatric HGGs using whole-exome
sequencing (WES) and compared them to 543 exomes
from non-cancer control samples. We identified mutations
in SETD2, a H3K36 trimethyltransferase, in 15 % of
pediatric HGGs, a result that was genome-wide significant
(FDR = 0.029). Most SETD2 alterations were truncating
mutations. Sequencing the gene in this cohort and another
validation cohort (123 gliomas from all ages and grades)
showed SETD2 mutations to be specific to high-grade
tumors affecting 15 % of pediatric HGGs (11/73) and 8 %
of adult HGGs (5/65) while no SETD2 mutations were
identified in low-grade diffuse gliomas (0/45). Further-
more, SETD2 mutations were mutually exclusive with
H3F3A mutations in HGGs (P = 0.0492) while they partly
overlapped with IDH1 mutations (4/14), and SETD2-
mutant tumors were found exclusively in the cerebral
hemispheres (P = 0.0055). SETD2 is the only H3K36
trimethyltransferase in humans, and SETD2-mutant tumors
showed a substantial decrease in H3K36me3 levels
(P \ 0.001), indicating that the mutations are loss-of-
function. These data suggest that loss-of-function SETD2
mutations occur in older children and young adults and are
specific to HGG of the cerebral cortex, similar to the H3.3
G34R/V and IDH mutations. Taken together, our results
suggest that mutations disrupting the histone code at
H3K36, including H3.3 G34R/V, IDH1 and/or SETD2
mutations, are central to the genesis of hemispheric HGGs
in older children and young adults.
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Introduction
Malignant primary brain and central nervous system (CNS)
tumors occur at an age-adjusted incidence rate of 7.3 out of
100,000 people across all ages and are the leading cause of
cancer-related death in children [9]. High-grade gliomas
[HGG; grade III and grade IV astrocytomas/glioblastoma
(GBM)] are highly aggressive and deadly brain tumors [9,
32] and are more commonly diagnosed in adults. GBM
remains essentially incurable despite decades of concerted
therapeutic efforts [5]. One impediment to treatment is that
GBM is diagnosed as a single pathological entity, which
cannot discriminate potential genetic drivers and molecular
subtypes. This impacts the design and outcome of clinical
trials and likely contributes to the apparent inherent resis-
tance of GBM to adjuvant therapies. Because of the similar
histology, current treatments for GBM in children are
driven by adult studies and show, as in adults, little ther-
apeutic success.
We and others recently identified two recurrent muta-
tions in H3F3A, which encodes the replication-independent
histone 3 variant H3.3, in over 30 % of pediatric and young
adult GBM [32, 42]. The mutations, K27M and G34R/
G34V, occur at positions in the histone tail that are critical
for post-translational modifications involved in the histone
code, which determines chromatin structure and gene
expression. H3.3 K27M mutations were also identified in
over 70 % of pediatric diffuse intrinsic pontine glioma
(DIPG), a fatal HGG of the brainstem [18, 42] as well as
K27M mutations in the canonical H3.1 in 18 % of samples
[42]. H3.3 mutations significantly overlapped with muta-
tions in TP53 and in ATRX (a-thalassemia/mental-
retardation syndrome-X-linked) [13, 40] and less fre-
quently with the ATRX hetero-dimer DAXX, which encode
subunits of a chromatin remodeling complex required for
H3.3 incorporation at pericentric heterochromatin and
telomeres [8, 13]. H3.3 mutations represent the pediatric
counterpart of the recurrent hotspot mutations in isocitrate
dehydrogenase 1 or 2 (IDH1/2) [27, 44]. IDH1 R132
mutations are gain-of-function, causing the enzyme to
produce 2-hydroxyglutarate (2-HG) [7, 27] and IDH1-
mutant tumors display distinct DNA methylation profiles
with global hypermethylation, termed a glioma-CpG island
methylator phenotype (G-CIMP) [26, 35, 38]. Interestingly,
similar to pediatric GBM, IDH1 mutations were shown to
occur in association with TP53 [3, 27] and ATRX mutations
in adult diffuse astrocytic tumors [14, 16, 25], illustrating
an important constellation of mutations in the development
of pediatric and secondary GBM. In the present study, we
sought to identify drivers of HGG in pediatric samples that
did not carry H3.3 or IDH mutations. We investigated a
cohort of 60 pediatric HGGs utilizing statistical analysis of
whole-exome sequencing (WES) on a genome-wide rank-
ing scale and validated results in an independent validation
cohort of 123 gliomas from all ages and grades. Herein, we
present data showing the importance and functional impact
of mutations in the H3K36 trimethyltransferase SETD2 in
HGGs of the cerebral hemispheres.
Materials and methods
Sample characteristics and pathological review
Samples were obtained with informed consent following
approval of the Institutional Review Board of individual
hospitals. Samples were reviewed by senior neuropathol-
ogists (S.A., A.K.) according to WHO guidelines. Fifty-
one pediatric grade IV astrocytomas (glioblastoma, GBM)
patients and nine pediatric grade III astrocytomas from
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patients aged 1–20 years were analyzed by whole-exome
sequencing (44 previously published in [32]). An addi-
tional 123 adult and pediatric gliomas of diverse histology
and grade were also included for targeted sequencing of
SETD2, IDH1 and H3F3A. Available clinical and relevant
mutational characteristics are detailed in Table S1. Tis-
sues were obtained from the London/Ontario Tumor
Bank, the Pediatric Cooperative Health Tissue Network,
the Children’s Oncology Group, The Montreal Children’s
Hospital and from collaborators in Poland, Hungary and
Germany.
DNA extraction
Genomic DNA was extracted from frozen tumor tissue
utilizing the Qiagen DNeasy Blood and Tissue kit
according to instructions from the manufacturer (Qiagen).
Alignment and variant calling for whole-exome
sequencing
Standard instructions from the manufacturer were used for
target capture with the Illumina TruSeq exome enrichment
kit and 100 bp paired-end sequencing reads on the Illumina
HiSeq platform with bioinformatic processing and variant
annotation as previously described [32]. For the selected
genes of interest shown in Table S1, variants in these genes
that were private to tumor samples are shown, i.e. those
variants not seen within the 1000 genomes (http://www.
1000genomes.org/) or NHLBI exome (http://evs.gs.
washington.edu/EVS/) databases, or in any of our 543
control exomes. Missense mutations were highlighted if
they occurred within highly conserved residues in verte-
brates, assessed utilizing the UCSC Genome Browser (http://
genome.ucsc.edu/) conservation track tool [17]. To assess
significance of mutations in our tumor dataset, we used a
case–control approach to compare the frequency of private
mutations in each gene in the 60 tumor exomes to 543
control exomes, which were from constitutional DNA of
patients with Mendelian diseases also sequenced at the
McGill University and Genome Quebec Innovation Centre
(Table S2). We controlled for false discovery rate using the
Benjamini–Hochberg procedure. All variants in these
genes are detailed in Table S2, whereas only private vari-
ants, likely to be somatic, and in highly conserved residues
(likely to impact function), are highlighted in Table S1 and
discussed in this study.
Targeted next-generation sequencing of SETD2
Coding regions of SETD2 were amplified using the
Fluidigm. Access Array system (http://www.fluidigm.com/
access-array-system.html) and sequenced on a half run of
the GS FLX Titanium system from Roche 454. Forty pairs
of primers were designed to cover all coding regions of the
21 exons of SETD2. Primers were designed using Primer3
(http://frodo.wi.mit.edu/primer3/) [28]. The parameters
were set to achieve melting temperatures ranging from 57
to 59 C. Lengths of PCR products are between 197 and
394 bp. The UCSC Genome Browser (http://genome.ucsc.
edu/) was used to download target genomic regions prior to
design and identify variants (based on dbSNP135: http://
www.ncbi.nlm.nih.gov/projects/SNP/) [17]. PCRs were
performed on 48 9 48 IFC (Integrated Fluidic Circuit)
chips. On each chip, 40 regions were amplified in 48
samples. Amplification of target regions and addition of
454 sequencing adapters and individual bar codes occur in
the same PCR performed on the Fluidigm FC1 cycler. All
samples were individually bar coded and sequenced in one
half-region of a GS FLX Titanium run. Validation of
variants was done with Sanger sequencing. Following this,
statistical analyses of Fisher’s exact test for contingency
comparisons were performed utilizing GraphPad Prism 5
software.
Immunoblotting analysis of H3K36me3 levels
in patient tumors
Fresh-frozen tumor tissues with adequate material and
known SETD2, H3F3A and IDH1 mutational status were
lysed using the EpiQuik Total Histone Extraction Kit
(Epigentek, USA). Lysates were quantified utilizing stan-
dard BioRad protein assay (BioRad) and loaded onto 15 %
acrylamide gels and run for 2 h at 100 V. Proteins were
transferred to polyvinylidene difluoride (PVDF) mem-
branes at room temperature for 5 min, using the Trans-
Blot Turbo transfer system (BioRad) at LOW MW setting,
blocked and immunoblotted with the following conditions
overnight at 4 C: rabbit polyclonal anti-H3K36me3
(Abcam #9050) at 1:1,000 in 5 % skim milk and rabbit
polyclonal anti-H3 (Abcam #1791) at 1:1,000 in 5 % skim
milk. Membranes were subsequently washed thrice
with tris-buffered saline-Tween 20 (TBS-T) and incubated
with horseradish peroxidase (HRP)-conjugated donkey
anti-rabbit IgG secondary antibody (GE Healthcare
#NA934V) at 1:5,000 with Precision Protein StrepTactin-
HRP conjugate at 1:10,000 (BioRad #161-0380) in 5 %
skim milk for 1 h at room temperature and revealed uti-
lizing Amersham ECL detection (Amersham Biosciences).
H3K36me3 bands from four independent blots were
quantified utilizing ImageQuant TL v2003.02 (Amersham
Biosciences), normalized to total H3, and normalized
ratios were compared statistically using two-tailed T test
for significance.
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Methylation array profiling
DNA extracted from a subset of pediatric HGGs demon-
strating defects in SETD2, IDH1, or H3F3A at G34 and
wild-type tumors (n = 36) was analyzed for genome-wide
DNA methylation patterns utilizing the HumanMethyla-
tion450 BeadChip according to the manufacturer’s
instructions (Illumina, San Diego, USA) at the McGill
University and Genome Quebec Innovation Centre. Of the
[480,000 probes on the methylation chip, we discarded
probes with C90 % sequence similarity to multiple geno-
mic locations, with sequence variants in the probe binding
region (1000 Genomes Project, SNPs with a minor allele
frequency C2/120), and probes located on sex chromo-
somes, leaving 392,904 autosomal probes for further
analysis. Subset-quantile within array normalization was
performed on beta values using the SWAN method [23].
For unsupervised hierarchical clustering, the top 8,000
most variable probes (by standard deviation) were utilized
with average linkage and Pearson correlation algorithms
across the dataset. Consensus clustering was performed
utilizing the k-means algorithm with 1,000 iterations on the
top 8,000 most variable probes in the dataset. Methylation
analysis was performed utilizing R (R version 2.14.2,
http://cran.r-project.org/) with Minfi and ConsensusClus-
terPlus loaded packages.
Results and discussion
SETD2 mutations affect a significant proportion
of pediatric HGGs
To identify genetic drivers in samples not carrying muta-
tions in IDH1 and H3F3A, we analyzed 60 pediatric HGG
tumors [grades III (n = 9) and IV (n = 51)] using WES (44
previously reported; Table S1) [32]. As matched normal
DNA was unavailable for the majority of tumors, we
identified private mutations that were present in tumors but
were absent from public databases (1000 genomes project
[24], NHLBI exomes) and from our set of 543 control
exomes, and considered these as candidate somatic muta-
tions. We compared the frequency of private mutations in
each gene between the 60 tumors and 543 controls using
Fisher’s exact test and used a false discovery rate threshold
(FDR) of 0.05 to correct for multiple tests. Our case–control
approach effectively corrects for the background rate of
mutations in each gene (which implicitly includes the
length of the gene and the mutability). We filtered out
variants that were predicted to be tolerated/benign/unknown
by both SIFT and PolyPhen-2 [1], and identified private
mutations that we considered as candidate somatic muta-
tions. The top genes by mutation frequency are shown in
Table S2. As expected, four genes previously associated
with pediatric HGG showed a highly significantly number
of mutations (TP53, H3F3A, ATRX, NF1) [32] (Table S2).
In addition, two genes not previously reported in HGG,
SETD2 and CSMD3, achieved genome-wide significance
(FDR = 0.029 and 0.031, respectively). For SETD2, this
significance was more striking when only truncating
mutations were considered (FDR = 0.0017), as no trun-
cating mutations were seen in 543 controls, but tumor
samples had frameshift (3), nonsense (1), and splicing (1)
variants. In addition, the three missense variants in tumor
samples occurred at highly conserved residues and were
computationally predicted as damaging by both SIFT and
Polyphen scores (Fig. 1a, b). In contrast, of the seven pri-
vate variants in the control samples (all missense), only one
is predicted damaging by both SIFT and Polyphen. H3.3
mutations occur at two positions within the histone tail
involved in key regulatory post-translational modifications,
K27 (directly) and K36 (indirectly). Driver loss-of-function
SETD2 mutations have recently been identified in two high-
grade cancers, renal cell carcinoma [6, 12] and early T-cell
precursor acute lymphoblastic leukemia [37]. The other
candidate gene, CSMD3 is expressed in adult and fetal
brains; however, its functions are yet unclear [33]. Hence,
we focused our next efforts on SETD2 as the top candidate
gene.
SETD2 mutations affect pediatric and adult HGGs
of the cerebral hemispheres
We expanded our sequencing analysis and next sequenced
SETD2 in 123 additional gliomas of various ages and grades
(Table 1; Table S1). Combining the discovery and the vali-
dation datasets, SETD2 mutations were identified in a total of
15 % of pediatric HGG (11/73) and 8 % of adult HGG
(5/65), and were not seen in low-grade diffuse gliomas (0/45)
(P = 0.0133; Table 1; Table S1). Except for one sample, all
mutations occurred in children above the age of 12, in ado-
lescents and in younger adults, mirroring the age range of
H3.3 G34R/V and IDH1 mutations in HGG (Fig. 1a; Figure
S1) [18–21, 32, 35]. Notably, all tumors carrying SETD2
mutations were localized in the cerebral hemispheres
(P = 0.0055). SETD2 mutations were mutually exclusive
with H3F3A mutations (P = 0.049) in HGGs (0/70), but
showed partial overlap with IDH1 R132 mutations (4/14),
TP53 (4/8) and ATRX (3/9) mutations (Table S1).
Missense/truncating mutations in SETD2 impair
trimethyltransferase activity of the enzyme and confer
distinct global DNA methylation signatures
SETD2 encodes the only H3K36 trimethyltransferase in
humans [11, 41]. To support computational predictions of
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the damaging nature of SETD2 mutations, we assessed
H3K36 trimethyltransferase activity in histone acidic
extractions of patient tissue samples through Western blot-
ting for H3K36me3 levels, an indicator of SETD2 activity
[11]. Immunoblot analysis revealed a significant decrease in
total H3K36me3 levels in SETD2-mutant gliomas (Fig. 2a),
as well as a significantly decreased normalized ratio of
H3K36me3 to total H3 levels in SETD2-mutant tumors
(P \ 0.001; Fig. 2b) showing loss-of-function as a result of
SETD2 missense/truncating mutations.
GBMs with epigenetic driver mutations such as H3.3
K27M or G34R/V, as well as those with IDH1 mutations,
display distinct DNA methylation profiles and clinical
characteristics. They also arise in distinct anatomic com-
partments, with IDH1- and H3.3 G34R/V-mutant tumors
 Age Grade SETD2 Mutation Brain Region 
1 IV p.R1686Q Frontal lobe 
12 IV p.P1470S Temporal lobe 
12 IV p.(S1002Ffs*4) Parietal lobe 
12 IV p.1385_1385del, p.R2490Q Frontal lobe 
12 III p.G1621R Cortex 
14 IV p.R2109X Temporal lobe 
14 IV p.V2272A Cortex 
15 IV NM_014159.6:c.6293+1G>A Frontal lobe 
17 IV p.(T305Qfs*35) Temporal lobe 
17 III p.(K583Sfs*17) Temporo-parietal lobe 
18 IV p.E498X Temporal lobe 
43 III p.(S342Qfs*17) Temporal lobe 
48 IV p.(K853Rfs*37) Occipital lobe 
50 IV p.S1660X Parietal lobe 
53 IV p.D868G Parietal lobe 
58 III p.R1625C Insular cortex 
AWS 1495-1549aa 
SET 1550-1673aa 
Post-SET 1674-1690aa 
WW 2394-2422aa 
SRI 2465-2559aa 
2564 
1495 
1550 
1690 
1674 
2465 
2559 
2394 
2422 
SETD2 
Missense Nonsense Frameshift Splicing Indel 
1 
a 
b 
Fig. 1 Missense/truncating
mutations of the H3K36
trimethyltransferase SETD2
identified in pediatric and adult
high-grade gliomas. a Patient
age, tumor grade, and affected
brain region of tumors with
SETD2 mutation. b Schematic
mapping type and distribution
of missense/truncating
mutations in SETD2 in 183
gliomas included in the study
Table 1 Frequencies of SETD2 mutations in 183 pediatric and adult
gliomas
Glioma Mutated Wild type Total Frequency (%)
Grade IV 12 85 97 12.37
Pediatric 9 51 60 15
Adult 3 34 37 8.11
Grade III 4 37 41 9.76
Pediatric 2 11 13 15.38
Adult 2 26 28 7.14
Grade II 0 45 45 0
Pediatric 0 23 23 0
Adult 0 22 22 0
Overall gliomas 16 167 183 8.7
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being restricted to areas of the cerebral hemispheres [18–21,
32, 35]. We and others have previously described the dis-
tinct heterogeneity of epigenetic profiles underlying HGGs
including GBM [2, 35, 36]. We thus sought to characterize
the DNA methylation profiles of 36 pediatric HGG tumors
with mutations likely to affect K36 methylation status,
using the Illumina 450K array platform as previously
described [35]. SETD2 mutations yielded global DNA
methylation patterns distinct from tumors with H3.3 G34R/
V mutations, but which partly overlapped with IDH1-
mutant methylation patterns (Fig. 3a–f). Notably, promot-
ers at OLIG1/2 loci, characteristically hypermethylated in
G34R/V-mutated samples, were not hypermethylated in
SETD2 mutants (Figure S2) [2, 35].
Mutations identified in candidate oncogenic drivers
and other genes involved in histone post-translational
modifications in HGGs
We further investigated our dataset for mutations in other
genes affecting PTM of H3K27 or H3K36 but which did
not reach the statistically significant mutation levels. Eight
distinct mammalian enzymes methylate H3K36 and share
the catalytic SET domain, but have varying preferences for
K36 residues in different methylation states (reviewed
in [41]). SETD2 is the only enzyme in humans to catalyze
H3K36 tri-methylation [11], while its mono- and/or
di-methylation is catalyzed by NSD1, NSD2, NSD3,
SETMAR, ASH1L, SMYD2 or SETD3 (reviewed in [41]).
We identified one missense and one nonsense mutation in
ASH1L (concurrently with SETD2 mutation) and SETD3
(1 missense mutation concurrently with SETD2 mutation).
One PGBM mutant for SETD2 also had a missense muta-
tion in UTX/KDM6A (H3K27 demethylase). This same
PGBM had a missense mutation in PBRM1, a gene fre-
quently mutated in renal cell carcinoma in association
with SETD2 [39]. We also identified two mutations in
KDM5C (H3K4 demethylase) (Table S1). Interestingly, no
mutations in the cancer-implicated histone methyltrans-
ferase EZH2 were identified. Mutations in these genes were
not prevalent enough to be statistically associated with
HGGs in our sample set; however, it remains possible that
they contribute to pathogenesis in a small fraction of HGG
cases.
Further investigation of the exome dataset revealed
previously described mutations in BRAF (V600E [30, 31],
5/60 pediatric HGG), which did not overlap with the epi-
genetic driver mutations we identify (Table S1; Fig. 2c).
Other alterations also previously described in GBM, which
may provide pathways alternative or complementary to
epigenomic dysregulation, included PTEN mutations (two
samples) which overlapped with H3.3 K27M while EGFR
mutation or amplification (three samples) and CDKN2A
mutation/loss (five samples) partially overlapped with
SETD2 mutations (Table S1). Truncating mutations in the
mismatch repair genes [10] MSH6 (three samples) and
MSH2 (one sample) were identified and were concurrent
with IDH1 (two samples) and SETD2 (three samples)
mutations. Of note, SETD2 mutations were absent in a
large cohort of 125 cases of medulloblastoma [15] another
major group of pediatric brain tumors.
Alteration of H3K36 post-translational modifications
characterize hemispheric adolescent and younger adult
HGG
Post-translational modification of resident histones modu-
lates the properties of chromatin, impacting cell state and
differentiation and determining the outcome of virtually all
DNA processes in eukaryotes. Methylation of H3K36 is a
key histone mark and has been widely associated with
active chromatin but also with transcriptional repression,
alternative splicing, DNA replication and repair, DNA
methylation and the transmission of memory of gene
expression from parents to offspring during development
(reviewed in [41]). We identify loss-of-function mutations
in SETD2, in 15 % of pediatric and 8 % of adult high-grade
gliomas in a cohort of 183 samples from all ages and
grades II–IV of glioma (Fig. 1a; Table S1). We further
show SETD2 mutations to be specific to high-grade tumors
(P = 0.013), to HGGs located within the cerebral hemi-
spheres (P = 0.005), and to be mutually exclusive with
H3.3 mutations we [18, 32] and others [42] previously
identified in pediatric high-grade astrocytomas (P =
0.049). SETD2 alterations overlapped with IDH1 mutations
in 4 of 14 tumors (Table S1). Strikingly, the oncometab-
olite produced by IDH1 mutations inhibits a plethora of
histone demethylases (KDMs) causing aberrant histone
methylation at defined residues including K27 and K36 and
a block to cell differentiation [4, 22, 29, 43]. We [21] and
others [14] have previously shown the association of ATRX
Fig. 2 Missense/truncating mutations in SETD2 impair H3K36
trimethyltransferase activity of the enzyme. a Western blot analysis
of histone acidic extracts of SETD2-mutant tumor samples demon-
strating a significant decrease in H3K36me3 levels, indicating
impaired H3K36 trimethyltransferase activity of the enzyme. b Den-
sitometric quantification of H3K36me3 levels assessed in four
independent blots demonstrating a significant decrease in
H3K36me3/Total H3 normalized ratios in SETD2-mutant tumors.
WT* = WT for SETD2, IDH1 and H3F3A. c Pie representation of
mutations directly or indirectly affecting H3K36 methylation
(H3K36me) in pediatric HGGs of the cerebral hemispheres
(n = 35) indicating that approximately half of these tumors display
defects, pointing to H3K36 dysregulation as a critical mechanism of
hemispheric high-grade gliomagenesis. d Schematic representation of
major genetic and epigenetic defects leading to altered H3K36
methylation in hemispheric HGGs
b
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and TP53 mutations in IDH1-mutant diffuse astrocytic
gliomas, and others have pointed to mutations in CIC and
1p19q loss in IDH1-mutant oligodendroglial tumors. Thus,
IDH1 mutations may require other key genetic events in a
specific context for full-blown tumorigenesis, which may
include SETD2 mutations as suggested by our cohort.
H3.3K36 methylation can be thus disrupted by H3.3 G34R/
V mutation, IDH mutations and the SETD2 mutations we
report herein (Fig. 2a, b). Furthermore, our current analysis
suggests that this histone mark is specifically altered in
hemispheric adolescent and younger adult HGG (Fig. 2c,
d) [2, 18, 19, 25, 32, 34, 35], and that the functional effect
differs between SETD2 and H3.3 mutations (Fig. 3; Figure
S2). Future studies directed towards elucidating the
importance of H3K36 methylation in cortical astrocytes
and neural progenitor cells, and its dysregulation in
tumorigenesis may lend insight into the regional specificity
of these defects, while improved understanding of the
consequences of altered chromatin remodeling induced by
these mutations will help guide alternative therapeutic
avenues for these deadly cancers.
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